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Standard chemotherapeutic agents used for the treatment of pre-cancerous skin lesions and non-melanoma skin
cancers are not completely effective. Several studies have suggested that repeated inﬂammatory sunburn
reactions, which include the induction of cyclooxygenase-2 (COX-2) and the subsequent production of
prostaglandins, play a role in skin cancer development. COX-2 inhibition has been demonstrated to be a potent
means of preventing skin cancer development in mice; however, COX-2 inhibitors alone are not effective as
chemotherapeutic agents. Data in a variety of cancer types suggest greater efﬁcacy in treating tumors with
combination chemotherapies. Therefore, we hypothesized that a combination of the chemotherapeutic agent
5-ﬂuorouracil (5-FU) and the COX-2 inhibitor and anti-inﬂammatory drug celecoxib would act synergistically to
regress tumors in a murine model of ultraviolet light B- (UVB-) induced carcinogenesis. We found that topical
treatment with 5-FU and celecoxib together was up to 70% more effective in reducing the number of UVB-induced
skin tumors than 5-FU treatment alone. Our data suggest that more effective chemotherapy regimens can be
developed to treat the millions of pre-cancerous and cancerous skin lesions that arise every year, which could
ultimately lead to a signiﬁcant reduction in costs and cosmetic defects (scarring) associated with surgical
interventions.
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Numerous studies have now demonstrated a role for the
cyclooxygenase-2 (COX-2) enzyme in the development of
many different types of tumors (Koki et al, 2002). These
include studies in the skin, which have revealed the
overexpression of COX-2 in skin and tumors after ultraviolet
(UV) light exposure (Buckman et al, 1998). In addition,
blocking COX-2 activity through the use of specific COX-2
inhibitors, such as celecoxib, has been demonstrated to
effectively inhibit the development of murine UVB-induced
skin tumors (Fischer et al, 1999; Orengo et al, 2002; Wilgus
et al, 2003a). Whereas COX-2 inhibitors have been suc-
cessfully used to combat the formation of tumors, when
used alone in chemotherapy protocols they have not been
effective in inducing the regression of established skin
tumors (Pentland et al, 1999; Fischer et al, 2003; Wilgus
et al, 2003b). While disappointing, the results presented
here and those of Fischer et al (2003) show that COX-2
inhibitors do have the potential to increase the effectiveness
of other drugs, thereby still being useful in a chemother-
apeutic regimen. Furthermore, the fact that COX-2 inhibitors
are anti-inflammatory (Wilgus et al, 2000) and have the
ability to reduce damage in the skin after exposure to
physical agents such as UV light (Wilgus et al, 2003a) or
ionizing radiation (Liang et al, 2003), suggests they could
potentially be used to combat the damage and negative
effects associated with the use of common topical
chemotherapy drugs.
5-Fluorouracil (5-FU) is a chemotherapy drug commonly
used for the treatment of solid tumors of the GI tract, breast,
pancreas, ovaries, and colon (Chu et al, 2003). This anti-
metabolite drug mimics uracil and is incorporated into RNA
and DNA, where it inhibits the thymidylate synthetase
enzyme necessary for DNA synthesis (Heidelberger et al,
1957; Chu et al, 2003). 5-FU is preferentially incorporated
into the DNA of rapidly proliferating tumor cells, subse-
quently leading to the destruction of the tumor. The
observation that the systemic use of this drug could resolve
pre-cancerous actinic keratoses (AK) lesions in the skin
(Falkson and Schulz, 1962) led to the development of
topical preparations (Dillaha et al, 1963). The topical
formulation Efudex (ICN Pharmaceuticals, Inc., Costa Mesa,
California), is now commonly prescribed to treat pre-
cancerous AK lesions, and sometimes non-melanoma skin
cancer (NMSC) lesions themselves. However, it displays
variable efficacy (Ashton et al, 1970; Belisario, 1973). Topical
5-FU’s utility and effectiveness are hampered by the fact that
there are dramatic side-effects associated with its use,
including irritation, pain, inflammation, scaling, erosion, and
even scarring (Tsuji et al, 1984; Gupta et al, 2001). These
side-effects and the resulting cosmetic problems often lead
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to sporadic use by patients, which can be a detriment to the
potency of this drug.
The value of the inflammatory phase induced by topical
5-FU to the regression of skin lesions has been debated for
many years. Several studies suggest that it is not necessary
for the resolution of the lesion (Breza et al, 1976; Pearlman
et al, 1986). Therefore, there could be value in combining
5-FU with an anti-inflammatory drug such as celecoxib.
The effectiveness of 5-FU is less than ideal, resulting in
incomplete lesion removal and common recurrences of the
treated skin lesions (Sander et al, 1997; Salim et al, 2003).
Therefore, enhancing the tumor fighting capabilities of 5-FU
by targeting additional pathways involved in tumor growth
may prove to be beneficial in inducing tumor regression.
Since celecoxib and 5-FU target different pathways to
inhibit tumor growth, and because COX-2 inhibitors have
been suggested to enhance the effectiveness of other
chemotherapeutic drugs, we studied the effects of the
addition of the COX-2 inhibitor celecoxib (Celebrex G. D.
Searle LLC, St. Louis, MO) to the standard chemother-
apeutic agent 5-FU (Efudex) on the regression of UVB-
induced murine skin tumors.
Results
Induction of PGE2 in unirradiated skin by 5-FU treat-
ment The effects of combination treatment with 5-FU and
celecoxib on PGE2 production in unirradiated skin were
assessed using an enzyme immunoassay (Table I). Three
weeks of topical 5-FU treatments caused a significant
increase in the levels of PGE2 in the skin compared to the
vehicle control (p¼0.0218), suggesting upregulation of
PGE2 may contribute to the observed inflammatory side-
effects of topical 5-FU treatment. Adding the COX-2
inhibitor celecoxib to the 5-FU treatments either directly
(5-FU/celecoxib) or indirectly (5-FUþ celecoxib) caused
PGE2 levels to return to those found in vehicle treated skin.
Celecoxib was able to effectively control 5-FU-induced
PGE2 production, implying anti-inflammatory agents have
the potential to limit the damaging effects of topical 5-FU
treatment.
Effects of combination treatment on tumor regression
In order to formally estimate differences in tumor multiplicity
between the treatment groups (Fig 1A), a repeated measures model was fitted to the data and an autoregres-
sion correlation structure was selected. Model results found
that there was a significant group  time interaction,
implying that the change in the total number of tumors over
time depends on the treatment group (po0.0001). The
number of tumors in vehicle-treated mice increased by an
average of 1.27 tumors per week (p¼ 0.0017), whereas
mice in the most effective treatment group (5-FU/celecoxib)
lost an average of 2.34 tumors per week (#po0.0001). The
other groups did not significantly change over time.
In addition to group  time interactions, group differ-
ences in tumor multiplicity (mean number of tumors per
mouse) were estimated from the model at the different
weeks of treatment. At the start of treatments (week 0),
there were no significant differences in tumor multiplicity
between the groups. Groups were declared statistically
Table I. PGE2 levels in unirradiated skin after
3 wk of treatmenta
Treatment PGE2 concentration (pg)
Vehicle 115  6.35
Celecoxib 120  4.91
5-FU 148  8.03
5-FU/celecoxib 113  6.10
5-FUþcelecoxib 122  22.16
aValues represent mean  standard error.
p¼ 0.0218 compared to vehicle treatments.
PGE2, prostaglandin E2; FU, fluorouracil.
Figure1
Chemotherapeutic efficacy of 5-fluorouracil (5-FU) and celecoxib.
The effect of 3 wk of topical treatments on the regression of ultraviolet
B- (UVB-) induced skin tumors was assessed by determining tumor
multiplicity, or the mean number of tumors per mouse (A) and mean
tumor size (B). Tumor counts and size measurements were performed
weekly over the treatment time course, with n¼ 10 mice per treatment
group. A  denotes fewer tumors with borderline significance (po0.05)
and  represents significantly fewer tumors (po0.01) compared to
5-FU. A # indicates a significant negative time  group interaction
over the treatment period (po0.0001). Tumor size is presented in mm2
(length  width).
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significant if the p-value was less than 0.01, whereas
p-values less than 0.05 but greater than 0.01 were
considered borderline significant. Pairwise analysis re-
vealed that after 3 wk of treatment, 5-FU had no significant
effect on tumor multiplicity compared to vehicle controls.
5-FU/celecoxib treated mice achieved a difference of 4.4
fewer tumors per mouse compared to 5-FU treated mice at
week 2 (p¼0.0146) and 7.2 less tumors by week 3 (p¼
0.0003). Therefore, 5-FU/celecoxib treatments were almost
70% more effective in reducing tumor number compared to
5-FU alone. Although not as effective as the direct addition
of celecoxib to 5-FU (5-FU/celecoxib), treating with the two
drugs separately (5-FUþ celecoxib) was also able to affect
tumor multiplicity. Mice in the 5-FUþ celecoxib treatment
group had an average of 3.9 less tumors compared to 5-FU
treated mice by week 3 (p¼ 0.0457), which corresponds to
nearly a 40% enhancement in tumor regression with the
5-FUþ celecoxib treatments. Although significant differ-
ences in tumor multiplicity were revealed between groups
over the treatment period, no statistically significant differ-
ences in the size of remaining tumors were found (Fig 1B).
Combination treatment effects on tumor cell proliferation
Besides causing a significant reduction in the average
number of tumors per mouse (Fig 1), combination treatment
with 5-FU and celecoxib resulted in a synergistic reduction
in the percentage of PCNA-positive cells within the
remaining tumors compared to 5-FU treatments alone (Fig
2). Tumors from both 5-FU/celecoxib (Fig 2A and C) and
5-FUþ celecoxib (Fig 2A and D) treatment groups con-
tained a significantly lower percentage of proliferating tumor
cells (po0.001) compared to tumors receiving only 5-FU
treatments (Fig 2A and B).
Effects of topical treatments on tumor PGE2 content
Although the addition of celecoxib to 5-FU had a profound
effect on tumor multiplicity (Fig 1) and could reduce 5-FU-
induced PGE2 levels in unirradiated skin (Table I), celecoxib
did not have an effect on PGE2 levels in skin tumors (Table
II). As in unirradiated skin, 5-FU treatment increased the
amount of PGE2 in skin tumors compared to vehicle-treated
tumors (po0.001), but the addition of celecoxib was not
able to significantly alter these levels. Similar results were
seen in uninvolved irradiated skin (data not shown). These
data suggest that celecoxib may have been acting
synergistically with 5-FU to reduce tumor numbers in a
PGE2-independent method.
Effects of combination treatment on tumor recurrence
Following the 3-wk treatment period, a random subset of
mice were chosen to remain in the study with no additional
treatments to determine the effect a combination treatment
strategy would have on the rate of tumor regrowth (Fig 3).
Figure 2
Effects of 5-fluorouracil (5-FU) and celecoxib on proliferation.
Immunohistochemical staining for proliferating cell nuclear antigen
(PCNA) was used to assess the levels of cellular proliferation within
remaining skin tumors after 3 wk of topical treatments. The
percentages of PCNA-positive cells per field were determined and
the mean percentage  standard error are depicted graphically in A.
Four  60 fields for each tumor section were analyzed, n¼ 6 tumors
per treatment group. Representative photomicrographs are shown
(  10 magnification): B-5-FU, C-5-FU/celecoxib, and D-5-FUþ
celecoxib. A  represents statistical significance compared to 5-FU
treatments, with a p value o0.001 according to a Student’s t test.
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The assessments for tumor multiplicity and tumor size
for the recurrence phase used the week 3 treatment values
as the baseline values. Using the same statistical modeling
described for Fig 1, a significant weeks variable was found
during the recurrence phase (weeks 1–3 post-treatment),
which denotes significant changes in tumor multiplicity over
time (p¼0.0001). But there were no significant time
 group interactions, so each group displayed increases
in tumor multiplicity at the same rate. Although the
combination of 5-FU and celecoxib did not affect the rate
of tumor regrowth, pairwise analyses indicated that 5-FU/
celecoxib mice still harbored significantly fewer tumors
during the 3-wk period following the discontinuation of
treatment, with an average of 6.7 fewer tumors than 5-FU
(p¼0.017). As in the treatment period, no significant
differences in the size of the tumors were found between
treatment groups (data not shown).
Discussion
The current treatment strategies for non-melanoma skin
cancers and pre-malignant lesions such as AK are less than
optimal. Treatment options most commonly include topical
chemotherapies, such as 5-FU (Efudex and similar drugs) or
surgical excision. Although topical therapies have an ad-
vantage over surgical interventions with regard to cost,
trauma, and cosmetic outcome, they too have disadvan-
tages. Current topical chemotherapy regimens have severe
side-effects, including inflammation, pain, erosion, crusting,
and scarring (Tsuji et al, 1984; Gupta et al, 2001), and there
is a significant risk of recurrence after treatment (Sander
et al, 1997; Salim et al, 2003). Whether this is a result of
compliance issues and erratic use of the drugs by the
patients due to the side-effects or a low drug efficacy
remains to be seen. In any case, patients with skin cancers
and pre-cancerous lesions need more effective treatments
and a larger variety of treatment options to choose from.
The pre-clinical studies presented here demonstrate the
potential value of combining a 5-FU, in a commonly used
formulation (Efudex), and celecoxib, a COX-2 inhibitor and
anti-inflammatory drug, as a new treatment option. Oral or
topical treatment with celecoxib alone has previously been
shown to have no effect on established skin tumors. But its
addition to 5-FU significantly enhanced this drug’s che-
motherapeutic power. The dose of 5-FU that was used for
these studies (0.5%) was a fraction of the dose typically
used in humans (5%). In fact, this dose, which was chosen
based on our preliminary toxicity studies, did not have a
therapeutic effect on UVB-induced tumors in the present
studies. Although this low dose of 5-FU when used alone
did not result in the expected regression of skin tumors, this
result does help illustrate the powerful synergism between
5-FU and celecoxib.
Although the combination treatments were able to
dramatically reduce the number of skin tumors in this study,
no significant effects on tumor size were found. This is likely
due to the fact that there were very few tumors left to
measure in the mice treated with the combination of the two
drugs. Therefore, we were likely measuring a subset of
tumors which were somewhat resistant to the treatments.
This inherent bias brought forth by the overwhelming
response of the majority of the tumors to the combination
treatments may also explain why there were no effects on
PGE2 levels in the tumors or a more pronounced reduction
in PCNA with the combination treatments.
Previously published studies have shown that COX
inhibitors can synergize with chemotherapeutic drugs as
well as enhance the anti-tumor effects of ionizing radiation
(Ogino, 1996; Kishi et al, 2000; Fischer et al, 2003; Milas
et al, 2003; Yao et al, 2003). The exact mechanism of how
the combination of treatments act in an additive manner is
not fully understood. In this study, the significant decrease
in PCNA-positive epidermal cells within remaining tumors in
mice treated with the combination of 5-FU and celecoxib
compared to 5-FU alone suggests that these drugs may
inhibit separate pathways of tumor cell proliferation.
Treatment with 5-FU inhibits proliferation via the inhibition
of DNA synthesis while celecoxib inhibits proliferation
through the blockade of the COX pathway. Another possible
explanation is that celecoxib was facilitating an enhanced
uptake of 5-FU into the tumor cells, leading to increased
regression of the tumors. An increase in toxicity and uptake
of 5-FU into cancer cells in vitro has been demonstrated
Table II. PGE2 levels in skin tumors after 3 wk of treatment
a
Treatment PGE2 concentration (pg)
Vehicle 183  6.79
Celecoxib 189  3.35
5-FU 218  3.26
5-FU/celecoxib 213  3.20
5-FUþcelecoxib 220  4.08
aValues represent mean  standard error.
po0.003 compared to vehicle treatments.
PGE2, prostaglandin E2; FU, fluoroururacil.
Figure 3
Effect of 5-fluorouracil (5-FU) and celecoxib on tumor recurrence.
The lasting effects of 3 wk of topical treatments on the recurrence of
skin tumors was assessed by monitoring tumor multiplicity over a 3-wk
period after topical treatments were discontinued (n¼ 5 mice per
treatment group, p¼ 0.017 compared to 5-FU).
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using other non-steroidal anti-inflammatory drugs (Ogino
and Hanazono, 1999; Ogino and Minoura, 2001; Mizutani
et al, 2002). This may account for some of the increased
tumor regression seen with the combination treatments,
since the direct addition of celecoxib to 5-FU (5-FU/
celecoxib) was more effective in destroying tumors than
when the treatments were given separately (5-FUþ
celecoxib). Further studies will be performed to determine
the in vivo mechanism of synergy between the two drugs
used here.
The recurrence phase of this study demonstrates the
need for continued treatment, since all treatment groups
displayed a similar rate of tumor regrowth once the topical
treatments were discontinued. These results are similar to
those described in a recently published report examining
the effects of treatment with a combination of oral celecoxib
and difluoromethylornithine on murine UVB-induced skin
tumors. As seen in our study, when the treatments were
discontinued, tumor regrowth occurred at the same rate in
the combination group as in all other treatment groups
(Fischer et al, 2003). It is plausible, however, based on the
fact that celecoxib can inhibit the development of new
tumors (Wilgus et al, 2003a, b), that continued treatments
with celecoxib alone during the regrowth phase would have
inhibited tumor recurrence in the combination 5-FU and
celecoxib treatment groups. Regardless, these studies and
those of Fischer et al (2003) suggest that some form of
treatment should be continued after tumors have under-
gone regression following a combination chemotherapy
regimen.
Whereas the addition of the anti-inflammatory drug
celecoxib to 5-FU was able to reduce PGE2 levels in
unirradiated skin and did result in the enhanced destruction
of UVB-induced skin tumors, we did not find evidence of
reduced PGE2 levels in irradiated and treated skin (data not
shown) or tumor tissue. The reduction in tumor number
without an associated decrease in PGE2 levels is not
entirely unexpected, as reports of celecoxib acting on tumor
cells in a PGE2-independent mechanism have been
reported (Hsu et al, 2000).
We initially expected the addition of celecoxib to the
treatment regimen to decrease the 5-FU mediated inflam-
mation in the skin. But the dose of celecoxib used in this
study did not reduce the inflammatory effects of topical
5-FU treatment. At the dose and combination used in this
study, celecoxib may have been acting solely to enhance
the effects of 5-FU as a chemotherapeutic agent in the
irradiated skin and tumors rather than acting as an anti-
inflammatory agent. These results were disappointing since
the side-effects associated with 5-FU treatment are likely
to severely hamper its proper use by patients and in turn
its efficacy. But because celecoxib combined with 5-FU
reduced PGE2 levels induced by 5-FU treatment in
unirradiated skin, we expect that a formulation containing
altered ratios of 5-FU and celecoxib can be developed
which would retain the ability to more effectively treat skin
tumors while alleviating the inflammation-related side-
effects associated with the use of 5-FU. Reducing inflam-
mation associated with topical chemotherapy treatments
could be an important goal, not only to increase patient
compliance but also because inflammation has been linked
with the progression of pre-malignant skin tumors to
squamous cell carcinomas (Berhane et al, 2002). Although
this study examined pre-cancerous skin tumors since these
are the type of lesions most commonly treated with topical
5-FU, it is plausible, based on the enormous synergism
seen with these two drugs, that they may be effective for the
treatment of NMSC lesions as well. In any case, the current
data suggest that the combination of 5-FU and celecoxib in
a topical formulation has the potential to be used in a
clinical setting as an improved chemotherapy regimen. This
treatment strategy is yet another step towards the ultimate
goal of enhancing the effectiveness of skin cancer
treatments and reducing the number of surgical excisions
performed on the millions of people with NMSC and pre-
cancerous skin lesions.
Materials and Methods
Animal treatments Female Skh/hr hairless mice (6–8 wk, Charles
River, Wilmington, Massachusetts) were used for the studies. The
mice were housed in the vivarium at the Ohio State University
according to the requirements established by the American
Association for Accreditation of Laboratory Animal Care. All
procedures were approved prior to beginning the study by the
appropriate Institutional Animal Care Utilization Committee. Mice
were exposed dorsally to 2240 J per m2 of UVB light (one minimal
erythemic dose) from Phillips FS40UVB lamps (American Ultravio-
let Company, Murray Hill, New Jersey), fitted with Kodacel filters
(Eastman Kodak, Rochester, New York) three times weekly for 16
wk. Four weeks following the end of UVB exposure (week 20), at
which point 100% of the animals had at least one pre-malignant
skin lesion, or papilloma, mice were randomly assigned to one of
five treatment groups (n¼ 10 mice per group). The mice received
one of the following daily topical treatments in a volume of 200 mL:
(1) vehicle (KY Jelly; Ortho Pharmaceutical Corp., Raritan,
New Jersey); (2) vehicle containing 2 mg celecoxib (Celebrex,
SC-58635, 4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-
bezenesulfonamide, G.D. Searle & Co., St Louis, Missouri), (3) 0.5%
5-FU (5% 5-FU cream diluted to 0.5% with vehicle) three times
weekly with vehicle treatments on remaining days; (4) 0.5% 5-FU
containing 2 mg celecoxib (5-FU/celecoxib) three times weekly
with celecoxib (2 mg) treatments on remaining days; or (5) 0.5%
5-FU in the morning and 2 mg celecoxib 6 h later (5-FUþ
celecoxib) three times weekly with celecoxib (2 mg) treatments on
remaining days. Due to toxicity problems seen in preliminary dose
trials, 5% 5-FU (5% Efudex cream) was diluted with KY to obtain
the 0.5% concentration used in the above treatments. Incidentally,
this 0.5% dose (Carac, Aventis Pharmaceuticals, Inc., Bridgewater,
New Jersey), although in a different delivery vehicle, is now being
used clinically (Gupta et al, 2001). Celecoxib was dissolved in
acetone (0.25 mg per mL of acetone) and mixed with vehicle or
0.5% 5-FU to obtain an even mixture at a concentration of 2mg per
200mL for celecoxib and 5-FU/celecoxib treatments, respectively.
The mice were subjected to the topical treatments described
above for a total of 3 wk. Age matched control mice (n¼ 3 mice per
group), that had not been exposed to UVB, received the same
treatments to assess the effect of the treatments on unirradiated
skin. Five mice per group were randomly chosen and euthanized
after 3 wk of topical treatments, 24 h after the last treatment. The
remaining five mice in each group were monitored for an additional
3 wk after the cessation of treatments, without additional drug
administration to determine tumor recurrence rates. The number of
tumors per mouse and the size of each tumor (width by length)
were determined weekly starting at week 19, the week prior to the
beginning of the topical treatments, until the time of euthanization.
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Immunohistochemical detection of proliferating cell nuclear
antigen (PCNA) Immediately following euthanization, skin sec-
tions and tumors were placed in 10% neutral-buffered formalin for
2 h, washed with PBS, processed, and embedded in paraffin
blocks. Tissue sections (5 mm) were cut and mounted onto
Superfrost Plus microscope slides (Fisher Scientific, Pittsburgh,
Pennsylvania). Immunohistochemical staining using a primary anti-
PCNA antibody (1:100; Signet Pathology Systems, Dedham,
Massachusetts) was used to detect PCNA-positive tumor cells
as previously described (Wilgus et al, 2003a). Image analysis was
used to quantitate the number of PCNA-positive tumor cells as well
as the total number of cells in each high power field (60  ). The
percentage of PCNA-positive cells per field was calculated. Four
high power fields were analyzed per tumor, and six tumors per
treatment group were analyzed.
Prostaglandin E2 (PGE2) enzyme immunoassay Biotrak enzyme
immunoassays (Amersham-Pharmacia, Piscataway, New Jersey)
were used according to the manufacturer’s instructions to
determine the concentration of PGE2 (pg) per 5 mg of total protein
isolated from whole tissue as described previously (Wilgus et al,
2003a). Tissues from 3 mice per group for unirradiated skin and 5
mice per group for irradiated skin were analyzed. For the analysis
of PGE2 content in tumors, at least 3 tumors per mouse were
pooled and 5 pooled samples per treatment group were used for
the analysis.
Statistical methods The Biostatistics Core at the Ohio State
University Comprehensive Cancer Center was consulted through-
out this project regarding the statistical analysis of tumor multi-
plicity and size. Basic descriptive statistics and graphs for tumor
number and size were generated to compare the five treatment
groups (vehicle, celecoxib, 5-FU, 5-FU/celecoxib and 5-FUþ
celecoxib) comparing the average number of tumors as well as
tumor size (length  width) for both the treatment and recurrence
phases of the study. Two separate repeated measures models
were fit in order to separately model data from the treatment and
post-treatment periods. The models were of the general form
Yijk¼ mþ aj þ bkþ gjkþ eijk, where i is the index for the mice, m is the
overall mean, aj is the mean for treatment group j, bk is the mean
for week k, and gjk is the interaction between treatment j and week
k. The error terms are assumed to be correlated within mice. The
first set of models compare the total number of tumors in all mice
from treatment weeks 0–3 (10 mice per group), and the second set
of models consider the mice (5 mice per group) used for the follow-
up period (weeks 1–3 post-treatment), using measurements at
week 3 as a covariate in the model to control for differences at the
beginning of the follow-up period. Additionally, difference in weeks
0–3 using only the mice that survived to the follow-up period were
estimated. The statistical significance of factors, treatment group,
time (measured in weeks), and the interaction between group
and time in the model were tested. Pairwise group estimates at
each week were also performed. All of the analyses were
conducted using SAS version 8.02 (SAS Institute Inc., Cary,
North Carolina). Statistical differences in PCNA and PGE2 levels
between the treatment groups were determined using a Student’s
t test generated using StatView software (Abacus Concepts,
Berkeley, California), where po0.05 was considered statistically
significant.
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